Study of all data on Roche's highly debated Tamiflu says it does help

A significant new study of Roche's ($RHHBY) blockbuster flu fighter Tamiflu has found that, while it has side effects, it can reduce symptoms by a day and keep some patients out of the hospital with complications, Reuters reports. The drug, which was heavily stockpiled by governments during a swine flu scare in 2009, has been hotly debated with contentions that it just doesn't do much. The new analysis, published in The Lancet on Friday, evaluated the data from all previously published and unpublished trials of Tamiflu. Story | More

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.